Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2004

View Archived Issues

First phase I/II data on the efficacy and safety of HuMax-CD20 in follicular lymphoma

TLK-199 shows promise in the treatment of MDS

New phase I data on the antitumor effects and safety of talabostat

Preclinical studies support the use of AQ4N to treat lymphoproliferative diseases

Update on the pharmacokinetics of erlosamide in healthy volunteers

NFkappaB-selective estrogen receptor ligand promising against rheumatoid arthritis

Plasmin-specific inhibitor shows potent antiinvasive and antiangiogenic effects in vitro

Triad Therapeutics sells p38 kinase inhibitor program to Novartis

Specific myosin activator may be useful for treatment of heart failure

Phase II glioblastoma multiforme study for 131I-TM-601

Tapestry advances development of lead oncolytic drugs

Pilot pharmacokinetic study for zolpidem lingual spray formulation

RxGen awarded phase I of fast track SBIR grant for Parkinson's research

Enrollment completed in phase III colonoscopy study of INKP-102

New prostaglandin I2 receptor antagonists in early development at Roche

Boehringer Ingelheim scientists report agents for the treatment of hepatitis C infection

Wyeth researchers develop an antibiotic from Micromonospora

Roche patent covers novel adenosine receptor modulators for Alzheimer's, Parkinson's, etc.

New adenosine receptor antagonists and their use described in Fujisawa patent

New treatments for Parkinson's disease claimed in Schering patent

Enrollment completed in first pivotal study of milnacipran for FMS

European marketing of Alvesco to commence in 2005

Positive findings from Bentley's phase II study of intranasal insulin in diabetics

PHX-1149 scheduled to enter clinic for type 2 diabetes in 2005

Phase IIa study of PA-457 in HIV patients

FTC requests extension for review of MDX-010 collaboration

Aventis spins off Novexel

PEG-Intron available in Japan in combination with Rebetol for HCV

Teikoku Hormone and Grelan Pharmaceutical to merge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...